Hims & Hers Still Envisions A Role in Weight Loss Treatment

Telehealth provider Hims & Hers Health is facing pressure amid uncertainty about its ability to sell knockoff versions of Novo Nordisk’s popular weight loss drugs.

Hims & Hers has been positioning its brand as an alternative to pharmaceutical giants. I Photo: Hims & Hers

The company warned that its sales could decline now that a shortage of the drugs has ended, causing shares to tumble nearly 20% despite beating earnings projections, Josh Nathan-Kazis and Janet H. Cho reported for Barron’s Daily.

Days after the Food and Drug Administration (FDA) declared an end to the shortage of Novo’s semaglutide drugs, Hims & Hers said its sales of compounded semaglutide could be constrained once its current inventory is depleted.

This is because compounding pharmacies must stop producing the drugs by May 22.

However, Hims & Hers CEO Andrew Dudum remains focused on expanding personalized treatments, supplements, and medications for conditions such as low testosterone and menopause.

He expects the company to continue offering weight loss treatments without copying existing drugs.

Hims reported fourth-quarter earnings of 11 cents per share and revenue of $481 million, surpassing analysts’ expectations, with sales nearly doubling compared to the same period in 2023.

The company ended 2024 with 2.2 million subscribers. Hims & Hers has been positioning its brand as an alternative to pharmaceutical giants—a potentially compelling stance under an FDA led by Robert F. Kennedy Jr., the Secretary of Health and Human Services and a longtime critic of big pharma.

For 2025, the company expects revenue of up to $2.4 billion and adjusted operating earnings of up to $320 million. It anticipates weight-loss drug sales to reach $750 million this year.